Welcome to our dedicated page for Certara SEC filings (Ticker: CERT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Certara, Inc. (NASDAQ: CERT) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Certara is a biosimulation and model‑informed drug development company whose common stock is registered on The Nasdaq Stock Market LLC under the symbol CERT, as disclosed in its Form 8‑K filings.
Investors can review current reports on Form 8‑K, which Certara uses to announce material events. Recent 8‑K filings include press releases for quarterly financial results, where the company reports revenue from biosimulation software and services, bookings, and updates to its full‑year financial outlook. Other 8‑K filings document corporate developments such as amendments to the company’s credit agreement and leadership changes, including the appointment of a new chief executive officer.
In addition to 8‑K reports, users can expect to find annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available), which typically provide more detailed discussions of Certara’s business, risk factors, and financial statements. Filings related to financing arrangements, such as amendments to term loan facilities, are also included and can offer insight into the company’s capital structure and borrowing costs.
Stock Titan enhances these documents with AI‑powered summaries that explain key sections of lengthy filings, helping readers quickly identify important information without reading every page. Real‑time updates from EDGAR ensure that new Certara filings appear promptly, while dedicated sections surface insider transaction reports on Form 4 and other ownership‑related disclosures when they are filed.
By using this page, investors and researchers can follow Certara’s regulatory reporting history, track material events, and better understand how the company describes its biosimulation software, services, and financial performance in official SEC documents.
Certara, Inc. president and chief commercial officer Leif E. Pedersen reported vesting and settlement of stock awards on April 1, 2026. He exercised restricted stock units and performance stock units to receive 33,167 shares of common stock at an exercise price of $0.00 per share.
He also received a separate award of 14,510 shares of common stock, while 11,611 shares were withheld at $5.70 per share to satisfy tax obligations tied to the RSU and PSU vesting. Following these compensation-related transactions, he directly holds 110,045 shares of Certara common stock.
Certara, Inc. executive Adrian McKemey, President, Drug Development Solutions, exercised 10,849 restricted stock units into common shares on April 1, 2026 at a stated price of $0.00 per share. These RSUs were granted on May 20, 2025 under Certara’s 2020 Incentive Plan.
In connection with vesting, 2,642 common shares valued at $5.70 per share were withheld to satisfy tax obligations, a non-market, tax-withholding disposition exempt under Rule 16b-3. After these transactions, McKemey directly holds 8,207 common shares and 21,698 unvested RSUs scheduled to vest in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. SVP and General Counsel Daniel Corcoran exercised restricted stock units into common shares as part of his equity compensation. On April 1, 2026, one-third of a prior RSU grant vested and settled, delivering 10,849 shares of common stock. Of these, 5,751 shares were withheld at $5.70 per share to cover tax obligations, a non-market, tax-withholding disposition. Following these transactions, Corcoran directly held 21,319 shares of Certara common stock. The remaining RSUs from this grant are scheduled to vest and settle in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. Chief Financial Officer John E. Gallagher reported a series of equity compensation transactions involving restricted stock units (RSUs), performance stock units (PSUs), and related common stock on April 1, 2026.
He exercised or converted derivative awards into a total of 50,605 shares of common stock and received an additional grant or award of 23,346 common shares. Following these transactions, he directly owned 95,371 shares of Certara common stock.
The filing also shows 25,108 shares of common stock were disposed of to satisfy tax withholding obligations at prices including $5.70 per share, rather than through open-market sales. Footnotes explain that the PSUs and RSUs were granted under Certara’s 2020 Incentive Plan and vested based on multi-year service and performance schedules.
Certara, Inc. executive Robert Aspbury, President, Predictive Tech, reported multiple equity compensation events on April 1, 2026. Previously granted performance stock units and restricted stock units vested and were settled into a total of 33,167 shares of common stock, consistent with the filing’s exercise summary.
To cover related tax obligations, the company withheld 22,411 shares at $5.70 per share under code F, a non‑market, tax-withholding disposition exempt under Rule 16b-3. Aspbury also received a 14,510-share common stock award as compensation and, following these transactions, directly owned 332,442 shares of Certara common stock.
Certara, Inc. Chief Human Resources Officer Rona Anhalt exercised restricted stock units and settled related taxes in shares. She converted 9,764 RSUs into 9,764 shares of common stock on April 1, 2026, as part of a grant made on May 20, 2025 under the 2020 Incentive Plan.
Of these vested shares, 3,062 were withheld to cover tax obligations linked to the RSU vesting, leaving 11,883 shares of common stock held directly after the transactions. One-third of the RSUs vested on April 1, 2026, with the remaining two-thirds scheduled to vest in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. is calling a virtual 2026 Annual Meeting of Stockholders on May 14, 2026 at 9:00 a.m. Eastern Time. Holders of 153,325,078 common shares as of March 20, 2026 may vote online, by phone, mail, or during the webcast.
Stockholders will vote on three items: electing Class III directors Arjun Bedi, Stephen McLean, and CEO Jon Resnick; ratifying RSM US LLP as independent registered public accounting firm for 2026; and approving, on an advisory basis, executive compensation. The Board recommends voting FOR all three proposals and highlights extensive governance practices, independence standards, committee structures, and director stock ownership requirements designed to align the Board with stockholders.
Certara, Inc. reported that board member Cynthia Collins has notified the company of her intention to resign as a Class II director and member of the Audit Committee. Her resignation will be effective on May 14, 2026, the date of Certara’s 2026 annual meeting of stockholders.
The company states that Ms. Collins’ decision to resign is not due to any disagreement with Certara regarding its operations, policies, or practices. This indicates a planned governance change rather than a dispute-driven departure.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Certara Inc common stock. The amendment explains that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The filing lists 0 shares with 0% voting and dispositive power and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.